CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas

A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and Szary syndrome, the most common types of cu... Author: VJHemOnc Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

CONCLUSIONS: Although PC-PTCL-NOS is an aggressive neoplasm, rare cases such as this might have a long-term survival. Furthermore, the late relapse mimicking MEITL is intriguing and exceptional, in spite the fact that MEITL is a primary intestinal T-cell lymphoma with a typical histopathology and immunophenotype. Detailed clinicopathological and molecular studies are mandatory to elucidate the clonal relationship of metachronous lymphomas, as this has important clinical implication for treatment. Evaluation of the non-tumoral intestinal mucosa for enteropathy and immunostaining for MATK might help to differentiate a mimick...
Source: Pathology, Research and Practice - Category: Pathology Authors: Tags: Pathol Res Pract Source Type: research
Cutaneous T-cell lymphomas are a heterogeneous collection of non-Hodgkin lymphomas that arise from skin-tropic memory T lymphocytes. Among them, mycosis fungoides (MF) and S ézary syndrome (SS) are the most common malignancies. Diagnosis requires the combination of clinical, pathologic, and molecular features. Significant advances have been made in understanding the genetic and epigenetic aberrations in SS and to some extent in MF. Several prognostic factors have been identified. The goal of treatment is to minimize morbidity and limit disease progression. However, hematopoietic stem cell transplantation, considered...
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
This study is a combination of population-based data and a single-center cohort.Participants: SEER-18 consists of a population-based sample of patients across the United States with a diagnosis of MF (n=6196). The UMN cohort included a cohort of 172 patients with MF treated at the UMN from 2005-2017.Results: In the SEER-18 cohort, relative risks were estimated using the standardized incidence ratios (SIR). Of the 6196 patients in the MF cohort there were 514 (8.3%) second cancer events (SIR 7.3, 95% confidence interval [CI] 6.7-7.9). Patients with MF were at substantially increased risk for both. non-Hodgkin (SIR 46.51, CI...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster II Source Type: research
Conclusions: Durvalumab/lenalidomide has significant clinical activity in patients with refractory/advanced CTCL, which will be formally evaluated in the Phase 2 portion of this trial. Responses were durable and ongoing, and treatment was well tolerated with a low toxicity profile. Dose escalation is planned up to lenalidomide 20 mg daily. Our preliminary results from patients on trial demonstrated that immune signatures on skin biopsies at baseline may be predictive of response to checkpoint blockade and yield insights into mechanisms of therapeutic resistance.DisclosuresQuerfeld: Acelion: Membership on an entity's Board ...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster II Source Type: research
ConclusionsPreliminary data from this ongoing study indicate that IL TTI-621 administration is well-tolerated and has single agent activity in heavily pre-treated MF/SS patients across various disease stages. The rapid responses observed occurred in both injected and non-injected lesions indicating a local-regional effect with initial evidence of distant abscopal or systemic effects. Enrollment in this study is continuing to evaluate the impact of weekly maintenance dosing and further characterize the systemic effect and durability of responses.DisclosuresQuerfeld: Kyowa: Membership on an entity's Board of Directors or adv...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
Conclusions: In pts with R/R NHL, active doses of Cami-T with acceptable safety profiles were identified for both B-cell and T-cell lymphoma during dose escalation of this study. Five out of the 10 pts on study with T-cell lymphoma treated in the 60, 80, or 100 µg/kg cohorts responded. Subtype-specific cohorts in the dose escalation portion of this study are underway to better define the recommended dose for expansion.Study sponsored by ADC Therapeutics. http://clinicaltrials.gov/show/NCT02432235.DisclosuresCollins: MSD: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria, Research Funding; Roche: Consul...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
Conclusion: In ongoing 2 stage expansion cohorts, cerdulatinib has shown good tolerability and sufficient activity in both PTCL and CTCL to proceed to the second stage. Significant efficacy includes both complete and durable responses across a spectrum of PTCL and CTCL subtypes. Correlative studies are aimed at identifying predictors of response. This phase 2a study will inform the design of a pivotal trial in T-cell lymphoma.DisclosuresHorwitz: Celgene: Consultancy, Research Funding; Forty Seven: Consultancy, Research Funding; Infinity/Verastem: Consultancy, Research Funding; Kyowa-Hakka-Kirin: Consultancy, Research Fundi...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: T Cell Lymphoma: Chemotherapy and Targeted Approaches Source Type: research
Cutaneous T-cell lymphomas (CTCL) represent up to 80% of extranodal non-Hodgkin Lymphomas, the most common being Mycosis Fungoides (MF) with or without its leukemic stage Sezary Syndrome and Primary cutaneous CD30+ T-cell lymphoproliferative disorders. Prognosis for advanced stages is poor, with 5-year survival 40-70% for patients with advanced skin stages, and 15-40% for those with extracutaneous involvement and CD30+ transformed CTCL. The disease is considered incurable, and most patients will undergo at least two different lines of therapy, and up to 36% undergo at least four different lines due to a short duration of r...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies Source Type: research
Primary cutaneous T-cell lymphomas are non-Hodgkin lymphomas of the skin defined by the presence of malignant T lymphocyte clonality.Mycosis fungoides (MF) accounts for more than half of these lymphomas, while CD30+ lymphoproliferative skin diseases (primary cutaneous anaplastic lymphoma and lymphomatiod papulosis (LyP)) comprise 25% of these neoplasms, and rarely seen tumors including subtypes of primary cutaneous peripheral T cell lymphoma nonspecified (NOS).A high expression of CD30 antigen on tumor cells is detected in primary cutaneous CD30+ lymphomas and transformed MF, whereas it may be observed in other entities, b...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies Source Type: research
Conclusion: GSK458 is active as a single agent or in combination with chemotherapy agents or small molecule inhibitors in a variety of T-cell pre-clinical models representing forms of systemic or cutaneous T-cell lymphoma. GSK458 was able to inhibit phosphorylation of AKT, mTOR and GSK3β, which may be the mechanism to reduce ATP production and glucose uptake in the cancer cells. Moreover, GSK458 arrested cell cycle at G1 arrest. Our data supports the clinical evaluation of GSK458 in relapsed/refractory T-cell lymphoma patients. (Supported by Roswell Park Cancer Institute Alliance Foundation Grant)DisclosuresNo relevan...
Source: Blood - Category: Hematology Authors: Tags: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Lymphoma | Mycosis Fungoides | T-cell Lymphoma